As of May, 9 The EPS for Charles River Laboratories International, Inc. (CRL) Expected At $1.25

April 17, 2018 - By Robert Reynolds

Charles River Laboratories International, Inc. (NYSE:CRL) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.08. That’s change of 0.38, from 2017Q3’s 1.46. 35 investors sold all, 98 reduced holdings as Charles River Laboratories International, Inc. ratio turned negative. 104 increased stakes while 39 funds bought stakes. Funds hold 44.57 million shares thus 0.83% less from 2017Q3’s 44.95 million shares.
Cambridge Advsrs accumulated 2,000 shs. State Street Corp holds 0.01% in Charles River Laboratories International, Inc. (NYSE:CRL) or 1.30M shs. State Treasurer State Of Michigan has 17,000 shs. Los Angeles Mgmt And Equity Research has invested 0.01% in Charles River Laboratories International, Inc. (NYSE:CRL). The New York-based Cornerstone Capital Limited Liability Com has invested 0.1% in Charles River Laboratories International, Inc. (NYSE:CRL). Amundi Pioneer Asset Inc reported 190,070 shs. Sei Investments reported 0.06% in Charles River Laboratories International, Inc. (NYSE:CRL). Texas Permanent School Fund reported 32,015 shs or 0.04% of all its holdings. Wright has invested 0.25% in Charles River Laboratories International, Inc. (NYSE:CRL). Aristotle Capital Boston Ltd invested in 1.14% or 142,861 shs. Charter Company reported 3,968 shs. Snyder Cap Mgmt Ltd Partnership has 0.37% invested in Charles River Laboratories International, Inc. (NYSE:CRL). Gemmer Asset Mngmt has invested 0.01% in Charles River Laboratories International, Inc. (NYSE:CRL). Brinker Capital reported 5,255 shs. Moreover, Edge Wealth Management Limited Liability Corp has 0.02% invested in Charles River Laboratories International, Inc. (NYSE:CRL).

Charles River Laboratories International, Inc. had 21 sales and 0 buys since January 2, 2018. This’s net activity of $10.85 million. MILNE GEORGE M JR sold $890,100 worth of stock or 7,740 shs. On Monday, February 26 3,868 shs were sold by Smith David Ross, worth $415,224. Barbo William D sold $250,741 worth of stock. CHUBB STEPHEN D had sold 2,872 shs worth $312,172. Another trade for 9,893 shs valued at $1.08M was made by Girshick Birgit on Tuesday, March 6.

Charles River Laboratories International, Inc. (NYSE:CRL)’s earnings report is expected On May, 9., according to Zacks. EPS of $1.25 is 3.10 % down from 2017’s $1.29 EPS. If the current EPS of $1.25 is accurate, CRL’s profit could hit $59.94M. After $1.40 EPS was announced last quarter, analysts now see negative EPS growth of -10.71 % for Charles River Laboratories International, Inc.. The stock increased 1.13% or $1.2 during the last trading session, reaching $107.25.Charles River Laboratories International, Inc. has volume of 156,246 shares. Since April 17, 2017 CRL has risen 21.28% and is uptrending. CRL outperformed the S&P 500 by 9.73%.

Charles River Laboratories International, Inc. (NYSE:CRL) Ratings Coverage

In total 10 analysts cover Charles River Labs (NYSE:CRL). “Buy” rating has 6, “Sell” are 0, while 4 are “Hold”. 60% are bullish. 14 are the (NYSE:CRL)’s analyst reports since November 2, 2017 according to StockzIntelligence Inc. On Monday, January 22 the firm has “Hold” rating given by SunTrust. On Thursday, November 2 the firm has “Hold” rating given by RBC Capital Markets. In Friday, November 10 report Bank of America maintained the stock with “Buy” rating. On Thursday, November 16 the firm earned “Buy” rating by SunTrust. On Wednesday, February 14 the firm earned “Overweight” rating by JP Morgan. On Monday, November 13 Jefferies maintained the shares of CRL in report with “Buy” rating. The stock rating was upgraded by SunTrust to “Buy” on Wednesday, February 14. On Monday, November 13 Robert W. Baird maintained Charles River Laboratories International, Inc. (NYSE:CRL) rating. Robert W. Baird has “Buy” rating and $117.0 target. On Tuesday, February 13 RBC Capital Markets maintained Charles River Laboratories International, Inc. (NYSE:CRL) with “Hold” rating. On Wednesday, March 14 Morgan Stanley maintained Charles River Laboratories International, Inc. (NYSE:CRL) rating. Morgan Stanley has “Equal-Weight” rating and $102 target.

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide.The firm is valued at $5.14 billion. It operates through three divisions: Research Models and Services , Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).The P/E ratio is 42.27. The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers.

Charles River Laboratories International, Inc. (NYSE:CRL) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.